Literature DB >> 17482143

High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation.

Alex Crowe1, Carlo Ballatore, Edward Hyde, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

A library of approximately 51,000 compounds was interrogated by high throughput screening (HTS) using a heparin-induced tau fibrillization assay. HTS was conducted with bacterially expressed recombinant tau fragment K18 and the reaction was monitored by thioflavine T fluorescence. Hits meeting criteria set for selection in HTS were further evaluated in a panel of assays designed (a) to confirm the initial results and (b) to identify possible false positives arising from non-specific mechanisms or assay-dependent artifacts. Two 2,3-di(furan-2-yl)-quinoxalines were confirmed as inhibitors of tau fibrillization with IC(50)s in the low micromolar range (l-3 microM). Among false positive hits, members of the pyrimidotriazines, benzofurans, porphyrins, and anthraquinone, inhibited tau fibrillization by generating peroxides via catalytic redox cycles due to the reducing agent dithiothreitol (DTT) in the assay. This study delineates focused strategies for HTS of tau fibrillization inhibitors that are relevant to drug discovery for Alzheimer's disease and related tauopathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482143      PMCID: PMC2646256          DOI: 10.1016/j.bbrc.2007.03.056

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

2.  A specific mechanism of nonspecific inhibition.

Authors:  Susan L McGovern; Brian T Helfand; Brian Feng; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-09-25       Impact factor: 7.446

Review 3.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  Ligand-dependent inhibition and reversal of tau filament formation.

Authors:  Carmen Chirita; Mihaela Necula; Jeff Kuret
Journal:  Biochemistry       Date:  2004-03-16       Impact factor: 3.162

5.  Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity.

Authors:  Kevin R Guertin; Lina Setti; Lida Qi; Rachel M Dunsdon; Brian W Dymock; Philip S Jones; Hilary Overton; Mathew Taylor; Glyn Williams; Joseph A Sergi; Karen Wang; Ying Peng; Marcia Renzetti; Rogely Boyce; Fiorenza Falcioni; Ralph Garippa; Andrée R Olivier
Journal:  Bioorg Med Chem Lett       Date:  2003-09-01       Impact factor: 2.823

6.  Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.

Authors:  Sayuri Taniguchi; Nobuyuki Suzuki; Masami Masuda; Shin-ichi Hisanaga; Takeshi Iwatsubo; Michel Goedert; Masato Hasegawa
Journal:  J Biol Chem       Date:  2004-12-17       Impact factor: 5.157

7.  Microtubule-stabilising drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments.

Authors:  John Q Trojanowski; Amos B Smith; Donna Huryn; Virginia M-Y Lee
Journal:  Expert Opin Pharmacother       Date:  2005-05       Impact factor: 3.889

8.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Authors:  C M Wischik; P C Edwards; R Y Lai; M Roth; C R Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 9.  Protein aggregation and neurodegenerative disease.

Authors:  Christopher A Ross; Michelle A Poirier
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

Review 10.  Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

Authors:  Daniel M Skovronsky; Virginia M-Y Lee; John Q Trojanowski
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

View more
  45 in total

1.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

2.  The acetylation of tau inhibits its function and promotes pathological tau aggregation.

Authors:  Todd J Cohen; Jing L Guo; David E Hurtado; Linda K Kwong; Ian P Mills; John Q Trojanowski; Virginia M Y Lee
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

3.  Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.

Authors:  Alex Crowe; Wenwei Huang; Carlo Ballatore; Ronald L Johnson; Anne-Marie L Hogan; Ruili Huang; Jennifer Wichterman; Joshua McCoy; Donna Huryn; Douglas S Auld; Amos B Smith; James Inglese; John Q Trojanowski; Christopher P Austin; Kurt R Brunden; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-08-18       Impact factor: 3.162

Review 4.  Modulation and detection of tau aggregation with small-molecule ligands.

Authors:  Edward Chang; Nicolette S Honson; Bhaswati Bandyopadhyay; Kristen E Funk; Jordan R Jensen; Sohee Kim; Swati Naphade; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

5.  In vitro aggregation assays using hyperphosphorylated tau protein.

Authors:  Dexin Sui; Mengyu Liu; Min-Hao Kuo
Journal:  J Vis Exp       Date:  2015-01-02       Impact factor: 1.355

6.  Differentiating Alzheimer disease-associated aggregates with small molecules.

Authors:  Nicolette S Honson; Ronald L Johnson; Wenwei Huang; James Inglese; Christopher P Austin; Jeff Kuret
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

Review 7.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 8.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

Review 9.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

10.  Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.

Authors:  Alex Crowe; Michael J James; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski; Carlo Ballatore; Kurt R Brunden
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.